

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: R. Williams *et al.*

Group Art Unit: 1615

Application No.: To Be Assigned

Examiner: J. Venkat

Filing Date: Concurrently herewith

Attorney Docket No.: 10071-037-999

For: TOPICAL COMPOSITIONS AND METHODS FOR  
TREATING PAIN

**INFORMATION DISCLOSURE STATEMENT**

**Mail Stop PATENT APPLICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. § 1.56 and § 1.97, enclosed is a List of References Cited by Applicant listing 103 references in reverse chronological order for the Examiner's convenience. These references were either cited by the Examiner or submitted on February 20, 2003 in parent Application No. 09/931,293, filed August 17, 2001. Copies will be submitted upon request by the Examiner.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the Form PTO-1449.

No fee is believed to be due for this submission pursuant to § 1.97(b), as an initial Office Action on the merits of the above-identified application has not been issued. Should any fee be required, however, please charge such fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: September 25, 2003



Beibing Gary Zhang (Reg. No. 47,331)

For: Samuel Abrams (Reg. No. 30,605)  
**PENNIE & EDMONDS LLP**  
1667 K Street, N.W.  
Washington, D.C. 20006  
(202) 496-4400

Enclosure

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. <b>10071-037-999</b>			APPLICATION NO. Unassigned	
				APPLICANT <b>R. WILLIAMS et al.</b>			
			FILING DATE Concurrently herewith			GROUP 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,461,600 B1	10/2002	Ford	424	78.02	
	AB	6,387,957 B1	5/2002	Frome	514	647	
	AC	6,255,302 B1	7/2001	Kelly et al.	514	217.05	
	AD	6,251,948 B1	6/2001	Weber et al.	514	634	
	AE	6,251,903 B1	6/2001	Cai et al.	514	249	
	AF	6,245,781 B1	6/2001	Upadhyay et al.	514	321	
	AG	6,242,448 B1	6/2001	Kelly et al.	514	254.02	
	AH	6,239,194 B1	5/2001	Standke et al.	523	200	
	AI	6,225,324 B1	5/2001	Poss et al.	514	316	
	AJ	6,218,391 B1	4/2001	Arvanitis et al.	514	242	
	AK	6,211,171 B1	4/2001	Sawynok et al.	514	211.13	
	AL	6,197,830 B1	3/2001	Frome	514	654	
	AM	6,191,165 B1	2/2001	Ognyanov et al.	514	523	
	AN	6,191,131 B1	2/2001	He et al.	514	246	
	AO	6,174,192 B1	1/2001	Watanabe et al.	439	377	
	AP	6,172,097 B1	1/2001	Cordi et al.	514	396	
	AQ	6,133,282	10/2000	Horvath et al.	514	292	
	AR	6,117,855	9/2000	Carlson et al.	514	90	
	AS	6,096,771	8/2000	Kojima et al.	514	379	
	AT	6,025,369	2/2000	Rosenquist et al.	514	311	
	AU	6,017,961	1/2000	Flores et al.	514	561	
	AV	6,004,964	12/1999	Farrar et al.	514	255	
	AW	5,985,586	11/1999	Daggett et al.	435	7.21	
	AX	5,981,513	11/1999	Kruse et al.	514	91	
	AY	5,962,477	10/1999	Mak	514	327	
	AZ	5,948,389	9/1999	Stein	424	45	

	BB	5,914,403	6/1999	Nichols et al.	546	162	
	BC	5,888,494	3/1999	Farrar et al.	424	78.05	
	BD	5,869,521	2/1999	Farrar et al.	514	422	
	BE	5,863,916	1/1999	Cai et al.	514	249	
	BF	5,849,762	12/1998	Farrar et al.	414	327	
	BG	5,834,465	11/1998	Olney	514	226.2	
	BH	5,817,699	10/1998	Flores et al.	514	647	
	BI	5,811,078	9/1998	Maycock et al.	424	45	
	BJ	5,798,093	8/1998	Farrar et al.	424	45	
	BK	5,783,700	7/1998	Nichols et al.	546	162	
	BL	5,763,445	6/1998	Kruse et al.	514	255	
	BM	5,760,023	6/1998	Farrar et al.	514	150	
	BN	5,744,458	4/1998	Kruse et al.	514	91	
	BO	5,708,168	1/1998	Keana et al.	540	520	
	BP	5,688,955	11/1997	Kruse et al.	546	276.4	
	BQ	5,667,773	9/1997	Farrar et al.	424	78.05	
	BR	5,648,396	7/1997	Young et al.	514	651	
	BS	5,646,151	7/1997	Kruse et al.	514	255	
	BT	4,989,607	2/1991	Keusch et al.	128	640	
	BU	4,920,101	4/1990	Minaskanian et al.	514	24	
	BV	4,808,414	2/1989	Peck et al.	424	449	
	BW	4,801,586	1/1989	Minaskanian et al.	514	212	
	BX	4,755,535	7/1988	Minaskanian et al.	514	947	
	BY	4,751,087	6/1988	Wick	424	449	
	BZ	4,615,699	10/1986	Gale et al.	604	897	

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	WO 95/23798	9/1995	PCT				
	CB	WO 95/18124	6/1995	PCT				
	CC	WO 95/16679	6/1995	PCT				
	CD	WO 94/13677	6/1994	PCT				
	CE	WO 94/13676	6/1994	PCT				
	CF	WO 94/13661	6/1994	PCT				
	CG	WO 94/13644	6/1994	PCT				
	CH	WO 94/13643	6/1994	PCT				
	CI	0 577 394 A1	1/1994	Europe				
	CJ	WO 93/10163	5/1993	PCT				
	CK	0 107 376 A1	5/1984	Europe				

<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
CL	"Handbook of Pharmaceutical Excipients," Edited by Arthur H. Kibbe, Ph.D., <u>Am. Pharm. Assoc.</u> , <b>3:292-294</b> , 2000.	
CM	J. Sawynok et al., "Peripheral Antinociceptive Action of Amitriptyline in the Rat Formalin Test: Involvement of Adenosine," <u>Pain</u> , <b>80:45-55</b> , 1999.	
CN	J. Sawynok et al., "Peripheral Antinociceptive Actions of Desipramine and Fluoxetine in an Inflammatory and Neuropathic Pain Test in the Rat," <u>Pain</u> , <b>82:149-158</b> , 1999.	
CO	"Cardinal Manifestations and Presentations of Diseases," <u>Harrison's Principles of Internal Medicine</u> , Edited by A. Fauci et al., <b>14:1:53-58</b> , 1998.	
CP	C. Stein et al., "Peripheral Morphine Analgesia", <u>Pain</u> , <b>71:119-121</b> , 1997.	
CQ	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Types of Dermal Drug Delivery," <u>Interpharm Press, Inc.</u> , p. 7, 1997.	
CR	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems," <u>Interpharm Press, Inc.</u> , pp. 87-93, 1997.	
CS	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems: Current Status," <u>Interpharm Press, Inc.</u> , p. 33-112, 1997.	
CT	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chaper 23 Opioid Analgesics and Antagonists," <b>9:521-525</b> , 1996.	
CU	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chaper 23 Opioid Analgesics and Antagonists," <b>9:529</b> , 1996.	
CV	Gennaro, Remington: The Science and Practice of Pharmacy, "Coarse Dispersions," <b>19(1):289</b> , 1995.	
CW	Wolfe et al., "Massive Dextromethorphan Ingestion and Abuse," <u>Am J. Emerg Med. P.</u> , <b>13:174-176</b> , 1995.	
CX	Jia-He Li et al., "Potent, Orally Active, Competitive N-Methyl-D-aspartate (NMDA) Receptor Antagonists Are Substrates for a Neutral Amino Acid Uptake System in Chinese Hamster Ovary Cells," <u>J. Med. Chem.</u> , <b>38:1955-1965</b> , 1995.	
CY	Olney et al., "NDMA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia," <u>Neuropsychopharmacology</u> , <b>13(4):335-345</b> , 1995.	
CZ	Yoneda et al., "Differential Profiles of Binding of a Radiolabeled Agonist and Antagonist at a Glycine Recognition Domain on the N-Methyl-D-Aspartate Receptor Ionophore Complex in Rat Brain," <u>J. Neurochem</u> , <b>62(1):102-112</b> , 1994.	
DA	N. Michalun et al., "Milady's Skin Care and Cosmetic Ingredients Dictionary," Milady Publishing Company, p. 242, 1994.	
DB	Bigge, "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists," <u>Biochem. Pharmacol. P.</u> , <b>45(8):1547-1561</b> , 1993.	
DC	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIA, Chemical Permeation Enhancers," <u>Pharm. Tech.</u> , <b>17:62-90</b> , 1993.	
DD	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIB, Chemical Permeation Enhancers," <u>Pharm. Tech.</u> , <b>17:68-76</b> , 1993.	
DE	P. Leeson, "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," <u>Drug Design for Neuroscience</u> , <b>pp. 338-381</b> , 1993.	
DF	Wong et al., "Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain," <u>Neuropsychopharmacology</u> , <b>8(4):337-344</b> , 1993.	
DG	Albers et al., "Tolerability of Oral Dextromethorphan in Patients With a History of Brain Ischemia," <u>Clinical Neurpharmacology</u> , <b>15(6):509-514</b> , 1992.	

DH	Faden et al., "Pharmacological Strategies in CNS Trauma," <u>TiPS</u> , 13:29-35, 1992.
DI	Steinberg et al., "Dextromethorphan Alters Cerebral Blood Flow and Protects Against Cerebral Injury Following Focal Ischemia," <u>Neuroscience Letters</u> , 133:225-228, 1991.
DJ	Meldrum et al., "Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease," <u>TiPS</u> , 11:379-387, 1990.
DK	Willetts et al., "The Behavioral Pharmacology of NMDA Receptor Antagonists," <u>TiPS</u> , 11:423-428, 1990.
DL	"Percutaneous Absorption," edited by R. Bronaugh et al., 2 <sup>nd</sup> Ed., Contents, 1989.
DM	Mayer et al., "Sites of Antagonist Action on N-Methyl-D-Aspartic Acid Receptors Studied Using Fluctuation Analysis and a Rapid Perfusion Technique," <u>Journal of Neurophysiology</u> , 60(2):645-663, 1988.
DN	Thurkauf et al., "Synthesis, Absolute Configuration, and Molecular Modeling Study of Ettoxadol, a Potent Phencyclidine-Like Agonist," <u>J. Med. Chem.</u> , 31:2257-2263, 1988.
DO	G. Eccleston, "Emulsions," Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick et al., 5:137-189, 1988.
DP	J. Dohner, "Development of Processes and Equipment for Rate-Controlled Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 349-364, 1987.
DQ	H. Wolff et al., "Development of Processes and Technology for Adhesive-Type Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 365-378, 1987.
DR	D. Bova et al., "Product Development and Technology Transfer for Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 379-396, 1987.
DS	A. Jacobson et al., "Enantiomeric and Diastereomeric Dioxadrols: Behavioral, Biochemical and Chemical Determination of the Configuration Necessary for Phencyclidine-Like Properties," <u>J. Pharmacol. Exp. Ther. P.</u> , 243(1):110-117, 1987.
DT	M. Rogawski, "Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-benzodiazepines," <u>TiPS</u> , 14:325-331, 1993.
DU	Grimwood et al., "Characterization of the Binding of [ <sup>3</sup> H]L-689,560, An Antagonist for the Glycine Site on the N-Methyl-D-Aspartate Receptor, to Rat Brain Membranes," <u>Molecular Pharmacology</u> , 41:923-930, 1992.
DV	Skolnick et al., "Monoaminergic Involvement in the Pharmacological Actions of Buspirone," <u>Br. J. Pharmac.</u> , 86:637-644, 1985.
DW	Wong et al., "A New Inhibitor of Norepinephrine Uptake Devoid of Affinity for Receptors in Rat Brain," <u>J. Pharm. Exp. Therap.</u> , 222(1):61-65, 1982.
DX	Kinemuchi et al., "Substrate Selectivity of Type A and Type B Monoamine Oxidase in Rat Brain," <u>J. Neurochem.</u> , 35(1):109-115, 1980.
DY	W. Griffin, "Classification of Surface-Active Agents by "HLB," <u>J. Soc. Cosmet. Chem.</u> , 311-326, 1949.

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.